Loading this company
Incyte Corporation
INCYPrices in USD
TickerWorth ScoreA66/100
What we think
Too wide to call. Our lenses land between $54.58 and $178.00, which is too broad to say where today’s price sits in it.
Price
$113.07USD down −$0.20 (−0.18%)
Quoted · Prices are delayed.
Why did it move today?
Nothing we can cite explains today’s move for this company.
Is it cheap?
Our range from 3 models, on today’s numbers
$54.58–$178.00
What the price needs: revenue growth of more than 25%/yr for 5 years (our model assumes 15.0%), or investors accepting a ~6.7% discount rate, vs the 8.9% our model uses.
Led by discounted cash flow (DCF) · Steady cash-flow business
Price $113.07Priced · Prices are delayed.
Is it a good business?
- Valuation67 out of 100
- Growth100 out of 100
- Financial health100 out of 100
- Past performance100 out of 100
Bull, base, bear
Our forward range over 12 months is part of Pro. See plans
The street
Analysts’ mean target
$129.50 across 24 analysts
The high and low of the analyst range is part of Pro. See plans
What does it do?
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It operates in the Biotechnology industry (Healthcare sector), headquartered in United States. The company employs roughly 2,844 people.
Key stats
52-week range$84.02–$132.60
- Open
- $113.96
- Day high
- $114.56
- Day low
- $112.02
- Previous close
- $113.27
- Volume
- 1,580,667 · 0.96× avg
- Average volume
- 1,644,467
- Market cap
- $22,919,032,832.00
- P/E (TTM)
- 14.40
- Earnings per share
- $7.85
- Beta
- 0.74
Prices are delayed. The feed does not say when these figures were taken.
What’s the latest?
- Disclosed another material event
- Reported quarterly or annual results
- Disclosed another material event
- Disclosed another material event
- Reported shareholder vote results
- Disclosed another material event
- Reported quarterly or annual results
Top news
No recent headlines we can cite for this company.
Insider trades
The 90-day buying-and-selling read is part of Pro. See plans
- Heeson LeeShares withheld (tax) · $54,235.82
- BAKER BROS. ADVISORS LPGrant / award ·
Not investment advice. TickerWorth Score is a model output.